Myalgic Encephalomyelitis-Chronic Fatigue Syndrome Common Data Element item content analysis.
Slavin, Mary D, Bailey, Hannah M, Hickey, Emily J et al. · PloS one · 2023 · DOI
Quick Summary
This study examined how well existing questionnaires measure the main symptoms of ME/CFS. Researchers looked at 38 different symptom-assessment tools and found they do a good job measuring physical symptoms like fatigue, sleep problems, and pain. However, most tools don't adequately measure how ME/CFS limits daily activities and participation in work, social life, and other important areas of life.
Why It Matters
This study is important because ME/CFS diagnosis and management rely heavily on symptom questionnaires, yet most existing tools inadequately capture how the disease disrupts patients' daily functioning and quality of life. By identifying these gaps, the research provides a roadmap for developing better assessment tools that could improve clinical diagnosis and help providers understand the full impact of ME/CFS on patients' lives.
Observed Findings
73.65% of items in ME/CFS measures linked to Body Functions (symptoms), with fatiguability (14.64%), energy level (11.04%), and sleep dysfunction (9.12%) most common.
25.62% of items assessed Activities and Participation, with mobility the most frequently measured domain (4.59%).
Only 0.73% of items addressed Environmental Factors that may affect ME/CFS outcomes.
38 out of 119 identified ME/CFS measures met inclusion criteria for this analysis.
Inferred Conclusions
Current ME/CFS patient-reported outcome measures have a symptom-focused bias and insufficiently assess functional limitations and participation restrictions in work, social engagement, and other daily activities.
Development of ME/CFS-specific measures incorporating more comprehensive activity and participation items is needed to better capture disease impact on patients' lives.
Computerized adaptive testing combined with robust symptom and activity-limitation item banks could improve the efficiency and comprehensiveness of ME/CFS assessment in clinical practice.
Remaining Questions
Do current measures' limitations in assessing activities and participation actually impact clinical diagnosis rates or delay recognition of ME/CFS in primary care?
Which specific activity domains are most important to ME/CFS patients and should be prioritized in new measure development?
What This Study Does Not Prove
This study does not test whether current measures are clinically effective for diagnosis or treatment monitoring—it only analyzes their content. It does not prove that developing new measures with more activity-limitation items will actually improve patient care or outcomes. The findings reflect a snapshot of available tools and do not establish causation for why current measures have these coverage patterns.
What is the optimal combination of symptom items and activity-limitation items needed for a clinically useful, psychometrically sound ME/CFS assessment tool?